When should we measure lipoprotein (a)?

European Heart Journal

Volumn 34, Issue 42, 2013, Pages 3268-3276

  Kostner, Karam M ^a   März, Winfried ^b,c,d   Kostner, Gerhard M ^c  

^a UNIVERSITY OF QUEENSLAND   (Australia)

^b UNIVERSITY OF HEIDELBERG   (Germany)

^c MEDICAL UNIVERSITY OF GRAZ   (Austria)

^d SYNLAB ACADEMY   (Germany)

Author keywords

Assay; Atherosclerosis; Guidelines; Myocardial infarction; Stroke

Indexed keywords

ACETYLCYSTEINE; ACETYLSALICYLIC ACID; ANABOLIC AGENT; APOLIPOPROTEIN A; C REACTIVE PROTEIN; CARNITINE; CORTICOTROPIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ESTROGEN; FIBRIC ACID DERIVATIVE; HEMOGLOBIN A1C; HEPATOCYTE NUCLEAR FACTOR 1; HEPATOCYTE NUCLEAR FACTOR 4; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INTERLEUKIN 6; LIPOPROTEIN A; LOW DENSITY LIPOPROTEIN; NICOTINIC ACID; PROGESTERONE; RALOXIFENE; TAMOXIFEN; TESTOSTERONE; TIBOLONE;

AFRICAN AMERICAN; APHERESIS; ATHEROSCLEROSIS; CARDIOVASCULAR RISK; CAUCASIAN; CEREBROVASCULAR ACCIDENT; CHOLESTASIS; CHROMOSOME 6Q; DIAGNOSTIC PROCEDURE; DNA RESPONSIVE ELEMENT; ENZYME ACTIVITY; ENZYME LINKED IMMUNOSORBENT ASSAY; GENETICS; GLOMERULUS FILTRATION RATE; HEART INFARCTION; HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; ISCHEMIC HEART DISEASE; KIDNEY FAILURE; KRINGLE DOMAIN; LIVER DISEASE; NEPHELOMETRY; NEPHROTIC SYNDROME; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PATHOGENESIS; PH; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN ASSEMBLY; PROTEIN BLOOD LEVEL; PROTEIN DEGRADATION; PROTEIN METABOLISM; PROTEIN SECONDARY STRUCTURE; PROTEIN SYNTHESIS; PROTEIN URINE LEVEL; REFERENCE VALUE; REVIEW; RISK ASSESSMENT; ROUGH ENDOPLASMIC RETICULUM; SINGLE NUCLEOTIDE POLYMORPHISM; TURBIDIMETRY; TURNOVER TIME;

ASSAY; ATHEROSCLEROSIS; GUIDELINES; MYOCARDIAL INFARCTION; STROKE;

APOPROTEIN(A); BLOOD SPECIMEN COLLECTION; CARDIOVASCULAR DISEASES; DIABETES MELLITUS; HORMONES; HUMANS; HYPOLIPIDEMIC AGENTS; KIDNEY FAILURE, CHRONIC; LIPOPROTEIN(A); LIVER DISEASES; PRACTICE GUIDELINES AS TOPIC; REFERENCE VALUES; RISK ASSESSMENT;

EID: 84890500741     PISSN: 0195668X     EISSN: 15229645     Source Type: Journal    
DOI: 10.1093/eurheartj/eht053     Document Type: Review

References (95)

1. Nordestgaard BG, Chapman MJ, Ray K, Boren J, Andreotti F, Watts GF, Ginsberg H, Amarenco P, Catapano A, Descamps OS, Fisher E, Kovanen PT, Kuivenhoven JA, Lesnik P, Masana L, Reiner Z, Taskinen MR, Tokgozoglu L, Tybjaerg-Hansen A. Lipoprotein(a) as a cardiovascular risk factor: current status. Eur Heart J 2010;31:2844-2853.
2. Bermudez V, Arraiz N, Aparicio D, Rojas E, Gotera D, Guerra X, Canelon R, Faria J, Sorell L, Amell A, Reyna N, Cabrera M, Mengual E, Cano R, Cano C, Velasco M. Lipoprotein(a): from molecules to therapeutics. Am J Ther 2010;17: 263-273.
3. Hsieh Wu J. Lipoprotein(a) in vascular disease, cancer and longevity. Chang Gung Med J 2011;34:555-564.
4. Dube JB, Boffa MB, Hegele RA, Koschinsky ML. Lipoprotein(a): more interesting than ever after 50 years. Curr Opin Lipidol 2012;23:133-140.
5. Berg K. A new serum type system in man. Acta Pathol Microbiol Scand 1963;59: 369-382.
6. Reiner Z, Catapano AL, De Backer G, Graham I, Taskinen MR, Wiklund O, Agewall S, Alegria E, Chapman MJ, Durrington P, Erdine S, Halcox J, Hobbs R, Kjekshus J, Filardi PP, Riccardi G, Storey RF, Wood D. ESC/EAS Guidelines for the management of dyslipidaemias: the Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). Eur Heart J 2011;32:1769-1818.
7. Holmer SR, Hengstenberg C, Kraft HG, Mayer B, Poll M, Kurzinger S, Fischer M, Lowel H, Klein G, Riegger GA, Schunkert H. Association of polymorphisms of the apolipoprotein(a) gene with lipoprotein(a) levels and myocardial infarction. Circulation 2003;107:696-701.
8. Emerging Risk Factors Collaboration, Erqou S, Kaptoge S, Perry PL, Di Angelantonio E, Thompson A, White IR, Marcovina SM, Collins R, Thompson SG, Danesh J. Lipoprotein(a) concentration and the risk of coronary heart disease, stroke, and nonvascular mortality. JAMA 2009;302:412-423.
9. Kamstrup PR, Tybjaerg-Hansen A, Steffensen R, Nordestgaard BG. Genetically elevated lipoprotein(a) and increased risk of myocardial infarction. JAMA 2009; 301:2331-2339.
10. McLean JW, Tomlinson JE, Kuang W-J, Eaton DL, Chen EY, Fless GM, Scanu AM, Lawn RM. cDNA sequence of human apolipoprotein(a) is homologous to plasminogen. Nature 1987;330:132-137.
11. Gries A, Nimpf J, Nimpf M, Wurm H, Kostner GM. Free and apoB-Associated Lpa-specific protein in human serum. Clin Chim Acta 1987;164:93-100.
12. Chawla A, Repa JJ, Evans RM, Mangelsdorf DJ. Nuclear receptors and lipid physiology: opening the X-files. Science 2001;294:1866-1870.
13. Chennamsetty I, Claudel T, Kostner KM, Baghdasaryan A, Kratky D, Levak-Frank S, Frank S, Gonzalez FJ, Trauner M, Kostner GM. Farnesoid X receptor represses hepatic human APOA gene expression. J Clin Invest 2011;121: 3724-3734.
14. Chennamsetty I, Claudel T, Kostner KM, Trauner M, Kostner GM. FGF19 signaling cascade suppresses APOA gene expression. Arterioscler Thromb Vasc Biol 2012;32: 1220-1227.
15. Frank S, Krasznai K, Durovic S, Lobentanz EM, Dieplinger H, Wagner E, Zatloukal K, Cotten M, Utermann G, Kostner GM, Zechner R. High level expression of various apolipoprotein (a)-isoforms by 'transferrinfection': the role of kringle-IV sequences in the extracellular association with low density lipoprotein. Biochemistry 1994;15:12329-12339.
16. Frank S, Durovic S, Kostner K, Kostner GM. Inhibitors for the in vitro assembly of Lp(a). Arterioscler Thromb Vasc Biol 1995;15:1774-1780.
17. Dieplinger H, Utermann G. The seventh myth of lipoprotein(a): where and how is it assembled? Curr Opin Lipidol 1999;10:275-283.
18. Jenner JL, Seman LJ, Millar JS, Lamon-Fava S, Welty FK, Dolnikowski GG, Marcovina SM, Lichtenstein AH, Barrett PH, de Luca C, Schaefer EJ. The metabolism of apolipoproteins (a) and B-100 within plasma lipoprotein (a) in human beings. Metabolism 2005;54:361-369.
19. Krempler F, Kostner GM, Bolzano K. Turnover of lipoprotein (a) in man. J Clin Invest 1980;65:1483-1490.
20. Kronenberg F, Ikewaki K, Schaefer JR, Konig P, Dieplinger H. Kinetic studies of atherogenic lipoproteins in hemodialysis patients: do they tell us more about their pathology? Semin Dial 2007;20:554-560.
21. Lawn RM, Boonmark NW, Schwartz K, Lindahl GE,Wade DP, Byrne CD, Fong KJ, Meer K, Patthy L. The recurring evolution of lipoprotein(a). Insights from cloning of hedgehog apolipoprotein(a). J Biol Chem 1995;270:24004-24009.
22. Kronenberg F, Trenkwalder E, Lingenhel A, Friedrich G, Lhotta K, Schober M, Moes N, Konig P, Utermann G, Dieplinger H. Renovascular arteriovenous differences in Lp[a] plasma concentrations suggest removal of Lp[a] from the renal circulation. J Lipid Res 1997;38:1755-1763.
23. Kostner KM, Maurer G, Huber K, Stefenelli T, Dieplinger H, Steyrer E, Kostner GM. Urinary excretion of apo(a) fragments. Role in apo(a) catabolism. Arterioscler Thromb Vasc Biol 1996;16:905-911.
24. Kostner KM, Jansen M, Maurer G, Derfler K. LDL-Apheresis significantly reduces urinary apo(a) excretion. Eur J Clin Invest 1997;27:93-95.
25. Utermann G, Menzel HJ, Kraft HG, Duba HC, Kemmler HG, Seitz C. Lp(a) glycoprotein phenotypes. Inheritance and relation to Lp(a)-lipoprotein concentrations in plasma. J Clin Invest 1987;80:458-465.
26. White AL, Rainwater DL, Lanford RE. Intracellular maturation of apolipoprotein[ a] and assembly of lipoprotein[a] in primary baboon hepatocytes. J Lipid Res 1993;34:509-517.
27. Valenti K, Aveynier E, Leaute S, Laporte F, Hadjian AJ. Contribution of apolipoprotein (a) size, pentanucleotide TTTTA repeat and C/T(+93) polymorphisms of the apo(a) gene to regulation of lipoprotein(a) plasma levels in a population of young European Caucasians. Atherosclerosis 1999;147:17-24.
28. Trommsdorff M, Kochl S, Lingenhel A, Kronenberg F, Delport R, Vermaak H, Lemming L, Klausen IC, Faergeman O, Utermann G. A pentanucleotide repeat polymorphism in the 5′ control region of the apolipoprotein(a) gene is associated with lipoprotein(a) plasma concentrations in Caucasians. J Clin Invest 1995;96: 150-157.
29. Kamstrup PR, Tybjaerg-Hansen A, Steffensen R, Nordestgaard BG. Pentanucleotide repeat polymorphism, lipoprotein(a) levels, and risk of ischemic heart disease. J Clin Endocrinol Metab 2008;93:3769-3776.
30. Brazier L, Tiret L, Luc G, Arveiler D, Ruidavets JB, Evans A, Chapman J, Cambien F, Thillet J. Sequence polymorphisms in the apolipoprotein(a) gene and their association with lipoprotein(a) levels and myocardial infarction. The ECTIM Study. Atherosclerosis 1999;144:323-333.
31. Zysow BR, Lindahl GE, Wade DP, Knight BL, Lawn RM. C/T polymorphism in the 5′ untranslated region of the apolipoprotein(a) gene introduces an upstream ATG and reduces in vitro translation. Arterioscler Thromb Vasc Biol 1995;15:58-64.
32. Kraft HG, Windegger M, Menzel HJ, Utermann G. Significant impact of the +93 C/T polymorphism in the apolipoprotein(a) gene on Lp(a) concentrations in Africans but not in Caucasians: confounding effect of linkage disequilibrium. Hum Mol Genet 1998;7:257-264.
33. Cox LA, Jett C, Hixson JE. Molecular basis of an apolipoprotein[a] null allele: A splice site mutation is associated with deletion of a single exon. J Lipid Res 1998;39:1319-1326.
34. Ogorelkova M, Gruber A, Utermann G. Molecular basis of congenital lp(a) deficiency: A frequent apo(a) 'null' mutation in caucasians. Hum Mol Genet 1999;8: 2087-2096.
35. Ogorelkova M, Kraft HG, Ehnholm C, Utermann G. Single nucleotide polymorphisms in exons of the apo(a) kringles IV types 6 to 10 domain affect Lp(a) plasma concentrations and have different patterns in Africans and Caucasians. Hum Mol Genet 2001;:815-824.
36. Parson W, Kraft HG, Niederstatter H, Lingenhel AW, Kochl S, Fresser F, Utermann G. A common nonsense mutation in the repetitive Kringle IV-2 domain of human apolipoprotein(a) results in a truncated protein and low plasma Lp(a). Hum Mutat 2004;24:474-480.
37. Clarke R, Peden JF, Hopewell JC, Kyriakou T, Goel A, Heath SC, Parish S, Barlera S, Franzosi MG, Rust S, Bennett D, Silveira A, Malarstig A, Green FR, Lathrop M, Gigante B, Leander K, de Faire U, Seedorf U, Hamsten A, Collins R,Watkins H, Farrall M. Genetic variants associated with Lp(a) lipoprotein level and coronary disease. N Engl J Med 2009;361:2518-2528.
38. Li Y, Luke MM, Shiffman D, Devlin JJ. Genetic variants in the apolipoprotein(a) gene and coronary heart disease. Circ Cardiovasc Genet 2011;4:565-573.
39. Ichinose A. Hyperlipoprotein (a)-emia determined by genetic polymorphisms in apolipoprotein (a) gene. Brain Nerve 2008;60:1307-1317.
40. Boerwinkle E, Leffert CC, Lin J, Lackner C, Chiesa G, Hobbs HH. Apolipoprotein (a) gene accounts for greater than 90% of the variation in plasma lipoprotein (a) concentrations. J Clin Invest 1992;90:52-60.
41. Lackner C, Boerwinkle E, Leffert CC, Rahmig T, Hobbs HH. Molecular basis of apolipoprotein (a) isoform size heterogeneity as revealed by pulsed-field gel electrophoresis. J Clin Invest 1991;87:2153-2161.
42. Geethanjali FS, Luthra K, Lingenhel A, Kanagasaba-Pathy AS, Jacob J, Srivastava LM, Vasisht S, Kraft HG, Utermann G. Analysis of the apo(a) size polymorphism in Asian Indian populations: Association with Lp(a) concentration and coronary heart disease. Atherosclerosis 2003;169:121-130.
43. Ronald J, Rajagopalan R, Cerrato F, Nord AS, Hatsukami T, Kohler T, Marcovina S, Heagerty P, Jarvik GP. Genetic variation in LPAL2, LPA, and PLG predicts plasma lipoprotein(a) level and carotid artery disease risk. Stroke 2011;42:2-9.
44. Lanktree MB, Anand SS, Yusuf S, Hegele RA. Comprehensive analysis of genomic variation in the LPA locus and its relationship to plasma lipoprotein(a) in South Asians, Chinese, and European Caucasians. Circ Cardiovasc Genet 2010;3:39-46.
45. Slunga L, Johnson O, Dahlen GH, Eriksson S. Lipoprotein(a) and acute-phase proteins in acute myocardial infarction. Scand J Clin Lab Invest 1992;52:95-101.
46. Maeda S, Abe A, Seishima M, Makino K, Noma A, Kawade M. Transient changes of serum lipoprotein (a) as an acute phase protein. Atherosclerosis 1989;78:145-150.
47. Ramharack R, Barkalow D, Spahr MA. Dominant negative effect of TGF-beta1 and TNF-Alpha on basal and IL-6-induced lipoprotein(a) and apolipoprotein(a) mRNA expression in primary monkey hepatocyte cultures. Arterioscler Thromb Vasc Biol 1998;18:984-990.
48. Mooser V, Berger MM, Tappy L, Cayeux C, Marcovina SM, Darioli R, Nicod P, Chiolero R. Major reduction in plasma Lp(a) levels during sepsis and burns. Arterioscler Thromb Vasc Biol 2000;20:1137-1142.
49. Schultz O, Oberhauser F, Saech J, Rubbert-Roth A, Hahn M, Krone W, Laudes M. Effects of inhibition of interleukin-6 signalling on insulin sensitivity and lipoprotein (a) levels in human subjects with rheumatoid diseases. PLoS One 2010;5:e14328.
50. Berthold HK, Laudes M, Krone W, Gouni-Berthold I. Association between the interleukin-6 promoter polymorphism -174G/C and serum lipoprotein(a) concentrations in humans. PLoS One 2011;6:e24719.
51. Kostner KM, Kostner GM. Factors affecting plasma lipoprotein(a) levels: role of hormones and other nongenetic factors. Semin Vasc Med 2004;4:211-214.
52. Kostner KM, Banyai S, Banyai M, Bodlaj G, Maurer G, Derfler K, Horl WH, Oberbauer R. Urinary apolipoprotein (a) excretion in patients with proteinuria. Ann Med 1998;30:497-502.
53. Kostner KM, Clodi M, Bodlaj G, Watschinger B, Horl W, Derfler K, Huber K. Decreased urinary apolipoprotein (a) excretion in patients with impaired renal function. Eur J Clin Invest 1998;28:447-452.
54. Kollerits B, Auinger M, Reisig V, Kastenbauer T, Lingenhel A, Irsigler K, Prager R, Kronenberg F. Lipoprotein(a) as a predictor of cardiovascular disease in a prospectively followed cohort of patients with type 1 diabetes. Diabetes Care 2006; 29:1661-1663.
55. Mora S, Kamstrup PR, Rifai N, Nordestgaard BG, Buring JE, Ridker PM. Lipoprotein (a) and risk of type 2 diabetes. Clin Chem 2010;56:1252-1260.
56. de Bruin T, van Barlingen H, van Linde-Sibenius Trip M, van Vuurst de Vries AR, Akveld MJ, Erkelens DW. Lipoprotein(a) and apolipoprotein B plasma concentrations in hypothyroid, euthyroid, and hyperthyroid subjects. J Clin Endocrinol Metab 1993;76:121-126.
57. Chennamsetty I, Kostner KM, Claudel T, Vinod M, Frank S, Weiss TS, Trauner M, Kostner GM. Nicotinic acid inhibits hepatic APOA gene expression: studies in humans and in transgenic mice. J Lipid Res 2012;53:2405-2412.
58. Kostner KM, Kostner GM. Lipoprotein(a): still an enigmä Curr Opin Lipidol 2002; 13:391-396.
59. Bruckert E, Labreuche J, Amarenco P. Meta-Analysis of the effect of nicotinic acid alone or in combination on cardiovascular events and atherosclerosis. Atherosclerosis 2010;210:353-361.
60. Boden WE, Probstfield JL, Anderson T, Chaitman BR, Desvignes-Nickens P, Koprowicz K, McBride R, Teo K, Weintraub W. Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy. N Engl J Med 2011; 365:2255-2267.
61. Schlueter W, Keilani T, Batlle DC. Metabolic effects of converting enzyme inhibitors: focus on the reduction of cholesterol and lipoprotein(a) by fosinopril. Am J Cardiol 1993;72:37H-44H.
62. Hoffmann U, Derfler K, Haas M, Stadler A, Brady TJ, Kostner K. Effects of combined low-density lipoprotein apheresis and aggressive statin therapy on coronary calcified plaque as measured by computed tomography. Am J Cardiol 2003;91: 461-464.
63. Jaeger BR, Richter Y, Nagel D, Heigl F, Vogt A, Roeseler E, Parhofer K, Ramlow W, Koch M, Utermann G, Labarrere CA, Seidel D. Longitudinal cohort study on the effectiveness of lipid apheresis treatment to reduce high lipoprotein (a) levels and prevent major adverse coronary events. Nat Clin Pract Cardiovasc Med 2009;6:229-239.
64. Kastelein JJ, Wedel MK, Baker BF, Su J, Bradley JD, Yu RZ, Chuang E, Graham MJ, Crooke RM. Potent reduction of apolipoprotein B and low-density lipoprotein cholesterol by short-Term administration of an antisense inhibitor of apolipoprotein B. Circulation 2006;114:1729-1735.
65. Rizzo M. Lomitapide, a microsomal triglyceride transfer protein inhibitor for the treatment of hypercholesterolemia. IDrugs 2010;13:103-111.
66. Roth EM, McKenney JM, Hanotin C, Asset G, Stein EA. Atorvastatin with or without an antibody to PCSK9 in primary hypercholesterolemia. N Engl J Med 2012;367:1891-1900.
67. Cannon CP, Shah S, Dansky HM, Davidson M, Brinton EA, Gotto AM, Stepanavage M, Liu SX, Gibbons P, Ashraf TB, Zafarino J, Mitchel Y, Barter P. Safety of anacetrapib in patients with or at high risk for coronary heart disease. N Engl J Med 2010;363:2406-2415.
68. Berg K, Dahlén G, Frick MH. Lp(a) Lipoprotein and pre-ß1-lipoprotein in patients with coronary heart disease. Clin Genet 1974;6:230-235.
69. Kostner GM, Avogaro P, Cazzolato G, Marth E, Bittolo-Bon G. Lipoprotein Lp(a) and the risk for myocardial infarction. Atherosclerosis 1981;38:51-61.
70. Klein JH, Hegele RA, Hackam DG, Koschinsky ML, Huff MW, Spence D. Lipoprotein (a) is associated differentially with carotid stenosis, occlusion, and total plaque area. Arterioscler Thromb Vasc Biol 2008;28:1851-1856.
71. Genser B, Dias KC, Siekmeier R, Stojakovic T, Grammer T, März W. Lipoprotein (a) and risk of cardiovascular disease -A systematic review and meta-Analysis of prospective studies. Clin Lab 2011;57:143-156.
72. von Eckardstein A, Schulte H, Cullen P, Assmann G. Lipoprotein(a) further increases the risk of coronary events in men with high global cardiovascular risk. J Am Coll Cardiol 2001;37:434-439.
73. Kostner KM, Huber K, Stefenelli T, Rinner H, Maurer G. Urinary apo(a) discriminates coronary artery disease patients from controls. Atherosclerosis 1997;129: 103-110.
74. Herrmann W, Quast S, Wolter K, Eger H, Kiessig ST, Hahmann H, Kreuter J, Molinari E. Determination of free apolipoprotein(a) in serum by immunoassay and its significance for risk assessment in patients with coronary artery disease. Clin Chem Lab Med 1999;37:21-28.
75. Ridker PM, Hennekens CH, Stampfer MJ. A prospective study of lipoprotein (a) and the risk of myocardial infarction. JAMA 1993;270:2195-2199.
76. Gudnason V. Lipoprotein(a): A causal independent risk factor for coronary heart disease? Curr Opin Cardiol 2009;24:490-495.
77. Tregouet DA, Konig IR, Erdmann J, Munteanu A, Braund PS, Hall AS, Grosshennig A, Linsel-Nitschke P, Perret C, DeSuremain M, Meitinger T, Wright BJ, Preuss M, Balmforth AJ, Ball SG, Meisinger C, Germain C, Evans A, Arveiler D, Luc G, Ruidavets JB, Morrison C, van der Harst P, Schreiber S, Neureuther K, Schafer A, Bugert P, El Mokhtari NE, Schrezenmeir J, Stark K, Rubin D, Wichmann HE, Hengstenberg C, Ouwehand W, Ziegler A, Tiret L, Thompson JR, Cambien F, Schunkert H, Samani NJ. Genome-wide haplotype association study identifies the SLC22A3-LPAL2-LPA gene cluster as a risk locus for coronary artery disease. Nat Genet 2009;41:283-285.
78. Shiffman D, Kane JP, Louie JZ, Arellano AR, Ross DA, Catanese JJ, Malloy MJ, Ellis SG, Devlin JJ. Analysis of 17 576 potentially functional SNPs in three casecontrol studies of myocardial infarction. PLoS One 2008;3:e2895.
79. Shiffman D, O'Meara ES, Bare LA, Rowland CM, Louie JZ, Arellano AR, Lumley T, Rice K, Iakoubova O, Luke MM, Young BA, Malloy MJ, Kane JP, Ellis SG, Tracy RP, Devlin JJ, Psaty BM. Association of gene variants with incident myocardial infarction in the Cardiovascular Health Study. Arterioscler Thromb Vasc Biol 2008;28: 173-179.
80. Erqou S, Thompson A, Di Angelantonio E, Saleheen D, Kaptoge S, Marcovina S, Danesh J. Apolipoprotein(a) isoforms and the risk of vascular disease: systematic review of 40 studies involving 58 000 participants. J Am Coll Cardiol 2010;55: 2160-2167.
81. Schunkert H, Konig IR, Kathiresan S, Reilly MP, Assimes TL, Holm H, Preuss M, Stewart AF, Barbalic M, Gieger C, Absher D, Aherrahrou Z, Allayee H, Altshuler D, Anand SS, Andersen K, Anderson JL, Ardissino D, Ball SG, Balmforth AJ, Barnes TA, Becker DM, Becker LC, Berger K, Bis JC, Boekholdt SM, Boerwinkle E, Braund PS, Brown MJ, Burnett MS, Buysschaert I, Carlquist JF, Chen L, Cichon S, Codd V, Davies RW, Dedoussis G, Dehghan A, Demissie S, Devaney JM, Diemert P, Do R, Doering A, Eifert S, Mokhtari NE, Ellis SG, Elosua R, Engert JC, Epstein SE, de Faire U, Fischer M, Folsom AR, Freyer J, Gigante B, Girelli D, Gretarsdottir S, Gudnason V, Gulcher JR, Halperin E, Hammond N, Hazen SL, Hofman A, Horne BD, Illig T, Iribarren C, Jones GT, Jukema JW, Kaiser MA, Kaplan LM, Kastelein JJ, Khaw KT, Knowles JW, Kolovou G, Kong A, Laaksonen R, Lambrechts D, Leander K, Lettre G, Li M, Lieb W, Loley C, Lotery AJ, Mannucci PM, Maouche S, Martinelli N, McKeown PP, Meisinger C, Meitinger T, Melander O, Merlini PA, Mooser V, Morgan T, Muhleisen TW, Muhlestein JB, Munzel T, Musunuru K, Nahrstaedt J, Nelson CP, Nothen MM, Olivieri O, Patel RS, Patterson CC, Peters A, Peyvandi F, Qu L, Quyyumi AA, Rader DJ, Rallidis LS, Rice C, Rosendaal FR, Rubin D, Salomaa V, Sampietro ML, Sandhu MS, Schadt E, Schafer A, Schillert A, Schreiber S, Schrezenmeir J, Schwartz SM, Siscovick DS, Sivananthan M, Sivapalaratnam S, Smith A, Smith TB, Snoep JD, Soranzo N, Spertus JA, Stark K, Stirrups K, Stoll M, Tang WH, Tennstedt S, Thorgeirsson G, Thorleifsson G, Tomaszewski M, Uitterlinden AG, van Rij AM, Voight BF, Wareham NJ, Wells GA, Wichmann HE, Wild PS, Willenborg C, Witteman JC, Wright BJ, Ye S, Zeller T, Ziegler A, Cambien F, Goodall AH, Cupples LA, Quertermous T, Marz W, Hengstenberg C, Blankenberg S, Ouwehand WH, Hall AS, Deloukas P, Thompson JR, Stefansson K, Roberts R, Thorsteinsdottir U, O'Donnell CJ, McPherson R, Erdmann J, Samani NJ. Large-scale association analysis identifies 13 new susceptibility loci for coronary artery disease. Nat Genet 2011;43:333-338.
82. A genome-wide association study in Europeans and South Asians identifies five new loci for coronary artery disease. Nat Genet 2011;43:339-344.
83. Tsimikas S, Bergmark C, Beyer RW, Patel R, Pattison J, Miller E, Juliano J, Witztum JL. Temporal increases in plasma markers of oxidized low-density lipoprotein strongly reflect the presence of acute coronary syndromes. J Am Coll Cardiol 2003;41:360-370.
84. Blencowe C, Hermetter A, Kostner GM, Deigner HP. Enhanced association of platelet-Activating factor acetylhydrolase with lipoprotein (a) in comparison with low density lipoprotein. J Biol Chem 1995;270:31151-31157.
85. Pepin JM, O'Neil JA, Hoff HF. Quantification of apo[a] and apoB in human atherosclerotic lesions. J Lipid Res 1991;32:317-327.
86. Antonicelli R, Testa R, Bonfigli AR, Sirolla C, Pieri C, Marra M, Marcovina SM. Relationship between lipoprotein(a) levels, oxidative stress, and blood pressure levels in patients with essential hypertension. Clin Exp Med 2001;1:145-150.
87. Shindo J, Ishibashi T, Kijima M, Nakazato K, Nagata K, Yokoyama K, Hirosaka A, Sato E, Kunii H, Yamaguchi N, Watanabe N, Saito T, Maehara K, Maruyama Y. Increased plasminogen activator inhibitor-1 and apolipoprotein (a) in coronary atherectomy specimens in acute coronary syndromes. Coron Artery Dis 2001;12: 573-579.
88. Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation 2002;106:3143-3421.
89. Greenland P, Alpert JS, Beller GA, Benjamin EJ, Budoff MJ, Fayad ZA, Foster E, Hlatky MA, Hodgson JM, Kushner FG, Lauer MS, Shaw LJ, Smith SC Jr, Taylor AJ, Weintraub WS, Wenger NK, Jacobs AK. 2010 ACCF/AHA guideline for assessment of cardiovascular risk in asymptomatic adults: A report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation 2010;122:e584-e636 Circulation. 90. AACE Lipid and Atheroscierosis Guidelines. Endocr Pract 2012;18(Suppl. 11): 1-78.
90. Di Angelantonio E, Gao P, Pennells L, Kaptoge S, Caslake M, Thompson A, Butterworth AS, Sarwar N, Wormser D, Saleheen D, Ballantyne CM, Psaty BM, Sundstrom J, Ridker PM, Nagel D, Gillum RF, Ford I, Ducimetiere P, Kiechl S, Koenig W, Dullaart RP, Assmann G, D'Agostino RB Sr, Dagenais GR, Cooper JA, Kromhout D, Onat A, Tipping RW, Gomez-de-la-Camara A, Rosengren A, Sutherland SE, Gallacher J, Fowkes FG, Casiglia E, Hofman A, Salomaa V, Barrett-Connor E, Clarke R, Brunner E, Jukema JW, Simons LA, Sandhu M, Wareham NJ, Khaw KT, Kauhanen J, Salonen JT, Howard WJ, Nordestgaard BG, Wood AM, Thompson SG, Boekholdt SM, Sattar N, Packard C, Gudnason V, Danesh J. Lipid-related markers and cardiovascular disease prediction. JAMA 2012;307:2499-2506.
91. Furie KL, Kasner SE, Adams RJ, Albers GW, Bush RL, Fagan SC, Halperin JL, Johnston SC, Katzan I, Kernan WN, Mitchell PH, Ovbiagele B, Palesch YY, Sacco RL, Schwamm LH, Wassertheil-Smoller S, Turan TN, Wentworth D. Guidelines for the prevention of stroke in patients with stroke or transient ischemic attack: A guideline for healthcare professionals from the American heart association/American stroke association. Stroke 2011;42:227-276.
92. Tate JR, Berg K, Couderc R, Dati F, Kostner GM, Marcovina SM, Rifai N, Sakurabayashi I, Steinmetz A. International Federation of Clinical Chemistry and Laboratory Medicine (IFCC) Standardization Project for the Measurement of Lipoprotein(a). Phase 2: selection and properties of a proposed secondary reference material for lipoprotein(a). Clin Chem Lab Med 1999;37:949-958.
93. Dati F, Tate JR, Marcovina SM, Steinmetz A. First WHO/IFCC International Reference Reagent for Lipoprotein(a) for Immunoassay -Lp(a) SRM 2B. Clin Chem Lab Med 2004;42:670-676.
94. Shih DQ, Dansky HM, Fleisher M, Assmann G, Fajans SS, Stoffel M. Genotype/phenotype relationships in HNF-4alpha/MODY1: haploinsufficiency is associated with reduced apolipoprotein (AII), apolipoprotein (CIII), lipoprotein(a), and triglyceride levels. Diabetes 2000;49:832-837.
95. Kostner KM, Kostner GM. Therapy of hyper-Lp(a). In: v. Eckhardstein A, ed. Handbook of Experimental Pharmacology. Springer 2005;170. p.519-536.